Recombinant protein was used as the immunogen for the recombinant NKX2.1 antibody.
NKX2.1/TTF-1 is a member of the NKx2 family of homeodomain transcription factors. It is expressed in epithelial cells of the thyroid gland and the lung. Nuclei from liver, stomach, pancreas, small intestine, colon, kidney, breast, skin, testes, pituitary, prostate, and adrenal glands are unreactive. Anti-NKX2.1 is useful in differentiating primary adenocarcinoma of the lung from metastatic carcinomas originating in the breast, mediastinal germ cell tumors, and malignant mesothelioma. It can also be used to differentiate small cell lung carcinoma from lymphoid infiltrates. Loss of expression in non-small cell lung carcinoma has been associated with aggressive behavior of such neoplasms. NKX2.1 reactivity is also seen in thyroid malignancies.
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Antibody Type:
Primary Antibody
Application Dilute:
Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)
Application Notes:
The stated application concentrations are suggested starting points. Titration of the recombinant NKX2.1 antibody may be required due to differences in protocols and secondary/substrate sensitivity.1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* VAT and and shipping costs not included. Errors and price changes excepted
